Tern’s Bruce Leith appointed Executive Chairman of Purple Transform

Tern Plc

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things (IOT) technology businesses, has announced that Bruce Leith, the Company’s Business Development Director, a non-board position, has been appointed as Executive Chairman of Purple Transform Limited.  Tern will be paid the fees for Bruce Leith’s services.

Purple Transform is a company that Sure Valley Ventures Enterprise Capital LP (SVV2) is invested in.  As announced on 2 March 2022, Tern has previously committed to invest up to £5 million in SVV2 over the 10-year life of SVV2. Tern has a 6.1% holding in SVV2.

Commenting, Ian Richie, Chairman of Tern, said: “As I have previously stated, Tern’s focus is on realisations, but we will take appropriate opportunities to utilise the skills and experience of the Tern team’s hands on approach to generate income for Tern, without detracting from our primary purpose.  Bruce’s appointment to assist Purple Transform will not only provide a modest income stream for Tern, but it is intended to help drive value creation in the Purple Transform business that Tern will benefit from through its holding in SVV2.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines targets a clearer view of GLP-1 and cancer care demand

Talking Medicines is showing why real-world healthcare conversations matter for investors tracking GLP-1, oncology and the next stage of life sciences market positioning.

GLP-1 cancer signals add a new investor angle

Early oncology signals from ASCO 2026 add a new investor angle to the GLP-1 story, with further research needed before clinical or commercial conclusions can be drawn.

Device Authority expands enterprise reach through IoT security partnership

Device Authority’s partnership with Xalient strengthens its enterprise IoT security positioning as regulated industries look for scalable, automated ways to manage connected device risk.

Pharma engagement shifts from reach to relevance

Pharma engagement is moving from broad reach to relevant messaging across connected patient journeys.

Device Authority partnership expands route into enterprise IoT security

Device Authority’s partnership with Xalient strengthens its enterprise IoT security positioning by placing KeyScaler within a managed, identity-led cybersecurity model for complex and regulated environments.

Tern increases convertible loan note investment in Talking Medicines

Tern has received £270,000 of new unsecured convertible loan notes from Talking Medicines, increasing its total convertible loan note holding to approximately £0.79 million while retaining a 23.8% equity stake.

Search